By Lehlohonolo Lehana.
Moderna Inc said on Thursday it is boosting manufacturing capacity for its Covid-19 vaccine and expects to make up to 3 billion doses in 2022, more than twice its previous forecast.
It also said it is increasing its expectations for 2021 vaccine production to between 800 million and 1 billion shots, raising the bottom of its range from 700 million.
The final number of inoculations will depend on how many are lower-dose formulations for boosters and immunisation for children. Moderna shots currently deploy 100 micrograms of vaccine substance but some future shots may use only 50 micrograms.
"As we look forward to next year, we just see so much need for primary vaccine, we are hearing it all over the world, and also boosters," Moderna president Stephen Hoge said in an interview.
"So depending upon ... how much the ordering that happens is third doses or paediatric doses at 50 micrograms, we could see up to 3 billion doses," he added. Moderna had previously said it expected to make 1.4 billion shots in 2022.
Moderna also said new data suggests its shots can be stored safely for up to three months at refrigerator temperatures, making it easier to get them to hard-to-reach areas that may not have access to freezers. “That might be a breakthrough that really matters in 2022 in Africa and across lower and middle-income countries,” Hoge said.
Wealthy governments have been trying to stock up on Covid-19 shots from Moderna and Pfizer Inc/BioNTech SE after safety concerns and production problems temporarily sidelined vaccines from AstraZeneca Plc and Johnson & Johnson.
But even as rich countries speed up their vaccine rollouts, other parts of the world are facing sharp upticks in cases and struggling to acquire needed shots.
India has recorded more than 300,000 cases each day and more than 2,000 deaths in the past week. Fewer than 10% of its more than 1.3 billion citizens have received one dose and only around 20 million are fully inoculated against the virus.
Moderna expects to double output at a drug substance plant in Switzerland run by Lonza Group AG and boost production in a Spain-based facility owned by Laboratorios Farmaceuticos ROVI SA more than two-fold. US plants will also raise output by more than 50%.
Moderna's two-dose vaccine uses messenger-RNA technology that programs cells to build immunity to the novel coronavirus.
The US drugmaker said it would begin making investments this year and that production boosts would start in late 2021 and carry into early 2022.
Moderna said it is in advanced talks for additional deals with other manufacturers to help make its shots. Moderna earlier this month announced shot production deals with Sanofi SA and Catalent Inc.
The company would need regulatory sign-off to start shipping vaccine at the higher, refrigerator-level temperatures.
So far, Johnson & Johnson and AstraZeneca have been the only major global drugmakers with authorised Covid-19 shots that can be stored without a freezer.
Meanwhile South Africa’s COVID-19 caseload has increased to 1 578 450 after 1 250 people were confirmed to have contracted the virus on Wednesday.
In addition, the country logged 48 more deaths, pushing the tally to 54 285 to date.
According to Health Minister, Dr Zweli Mkhize, 19 fatalities occurred in the North West, 11 in the Eastern Cape and five in the Northern Cape.
In addition, Gauteng and the Free State recorded four deaths each, while one was reported in KwaZulu-Natal.
The cumulative recoveries now stand at 1 503 611, representing a recovery rate of 95%, and there are 20 554 active cases.
The information is based on the 10 590 107 tests conducted of which 22 514 were performed in the last 24 hours.
The Minister said the number of healthcare workers vaccinated under the Sisonke Protocol to date is 298 153 after the Johnson & Johnson trial resumed on Wednesday.
"Our last recorded cumulative vaccinations were 292 623 on 13 April 2021," he added.
Globally, there have been 148 329 348 confirmed cases of COVID-19, including 3 128 962 deaths, reported to the World Health Organisation (WHO).
In addition, 983 410 283 vaccine doses have been administered as of 28 April 2021.